Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo (Q56898738)

15

object named as

Ignacio Melero

0 references

author name string

Natalia Suarez

1

0 references

Carlos Alfaro

2

0 references

Juan Dubrot

3

0 references

Asis Palazon

4

0 references

Elixabet Bolaños

5

0 references

Lorena Erro

6

0 references

Sandra Hervas-Stubbs

7

0 references

Ivan Martinez-Forero

8

0 references

Aizea Morales-Kastresana

9

0 references

Salvador Martin-Algarra

10

0 references

Bruno Sangro

11

0 references

Fernando Lecanda

12

0 references

Jose L Perez-Gracia

13

0 references

Alvaro Gonzalez

International Journal of Cancer

14

0 references

language of work or name

English

0 references

publication date

15 July 2011

0 references

published in

0 references

volume

129

0 references

issue

2

0 references

page(s)

374-86

0 references

cites work

The B7 family revisited

1 reference

CD28 and CTLA-4 coreceptor expression and signal transduction

21 January 2018

1 reference

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

21 January 2018

1 reference

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

21 January 2018

1 reference

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

21 January 2018

1 reference

CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance

21 January 2018

1 reference

Control of regulatory T cell lineage commitment and maintenance

21 January 2018

1 reference

Mechanisms of foxp3+ T regulatory cell-mediated suppression

21 January 2018

1 reference

Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade

21 January 2018

1 reference

Cytotoxic T lymphocyte-associated molecule-4, a high-avidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail

21 January 2018

1 reference

B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse

21 January 2018

1 reference

CTLA-4 trafficking and surface expression

21 January 2018

1 reference

The B7 family and cancer therapy: costimulation and coinhibition

21 January 2018

1 reference

The interaction properties of costimulatory molecules revisited.

21 January 2018

1 reference

The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A.

21 January 2018

1 reference

Molecular basis of T cell inactivation by CTLA-4

21 January 2018

1 reference

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

21 January 2018

1 reference

CTLA-4 control over Foxp3+ regulatory T cell function

21 January 2018

1 reference

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy

21 January 2018

1 reference

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

21 January 2018

1 reference

Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206).

21 January 2018

1 reference

Cytotoxic T-lymphocyte-associated antigen-4.

21 January 2018

1 reference

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma

21 January 2018

1 reference

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues

21 January 2018

1 reference

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

21 January 2018

1 reference

Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.

21 January 2018

1 reference

Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes

21 January 2018

1 reference

Phase I/II trial of tremelimumab in patients with metastatic melanoma

21 January 2018

1 reference

Generation of Epstein-Barr Virus (EBV)-immortalized B cell lines

21 January 2018

1 reference

The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN gamma.

21 January 2018

1 reference

Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma

21 January 2018

1 reference

Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

21 January 2018

1 reference

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

21 January 2018

1 reference

Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes

21 January 2018

1 reference

Reversal of the TCR stop signal by CTLA-4

21 January 2018

1 reference

Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines

21 January 2018

1 reference

CD4 cells can be more efficient at tumor rejection than CD8 cells

21 January 2018

1 reference

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

21 January 2018

1 reference

Anti-CTLA4 antibody-induced lupus nephritis

21 January 2018

1 reference

CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance

21 January 2018

1 reference